Phase 2 N=296 Therapy for Pediatric Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 43 percentage of participants with response
Phase 2 N=150 Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease. — 45.3; 81.1; 116.4; 170.9 titers
Phase 2 N=243 Revaccination With Influenza Vaccine GSK1247446A
Influenza · Influenza, Human
Primary: Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms — 8; 5; 1; 2 Subjects
Phase 2 N=36 Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome
Primary: Colonic Transit Geometric Center at 24 Hours — 3.12; 3.05; 2.77 units on a scale
Phase 2 N=285 A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease
Dry Eye Syndromes
Primary: Changes in Corneal Staining Scores for Study Eye From Baseline at Week 8 — -3.0; -3.0; -3.0; -3.1 Units on a scale
Phase 2 N=296 Continuous Treatment Study of Topiramate in Migraine Participants
Migraine
Primary: Number of Participants With Adverse Events — 110; 85; 79 Participants
Phase 2 N=59 Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
Hepatocellular Carcinoma · Liver Cancer
Primary: Progression-free Survival (PFS) Rate — 64 percentage of participants
Phase 2 N=40 Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Liver Fat Content Change From Baseline to Six Weeks Post H.Pylori Treatment — 2.46; 3.61 percentage of liver fat content
Phase 2 N=387 A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine
Migraine
Primary: Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 — 5.9; 6.2; 6.6; -0.9 Migraine attacks — p=0.1646
Phase 2 N=63 Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Fragile X Syndrome
Primary: Aberrant Behavior Checklist Irritability Subscore — -5.1; -5.3 Points on a scale — p=0.05
Phase 2 N=33 Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease
Crohn's Disease
Primary: Safety and Tolerability of Ciprofloxacin — 25; 11; 9; 1 Adverse events
Phase 2 N=94 Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence
Urinary Incontinence
Primary: Percentage of Participants With a Decrease in Leakage Events of 30% or More. — 60.6; 61.7 Percentage of participants — p=.92
Phase 2 N=20 Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Incidence of Graft Rejection for Patients at Day 100 — 0 participants
Phase 2 N=567 Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia
Postherpetic Neuralgia
Primary: Change in Mean Pain (NRPS) From Baseline to Endpoint in Mean Pain — -1.9447; -1.9786; -1.6798; -1.6633 Points